Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hannah C Slater

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
The Lancet. Infectious Diseases|January 18, 2020
Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling studyHannah C Slater, Brian D Foy, Kevin Kobylinski, et al.
The Journal of Infectious Diseases|February 9, 2017
Pfhrp2-Deleted Plasmodium falciparum Parasites in the Democratic Republic of the Congo: A National Cross-sectional SurveyJonathan B Parr, Robert Verity, Stephanie M Doctor, et al.
Lancet (London, England)|March 18, 2019
Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trialBrian D Foy, Haoues Alout, Jonathan A Seaman, et al.
Molecular Biology and Evolution|September 8, 2020
Evaluating the Performance of Malaria Genetics for Inferring Changes in Transmission Intensity Using Transmission ModelingOliver J Watson, Lucy C Okell, Joel Hellewell, et al.
JMIR Research Protocols|March 20, 2023
Repeat Ivermectin Mass Drug Administrations for Malaria Control II: Protocol for a Double-blind, Cluster-Randomized, Placebo-Controlled Trial for the Integrated Control of MalariaBrian D Foy, Anthony Some, Tereza Magalhaes, et al.
Nature|December 4, 2015
Assessing the impact of next-generation rapid diagnostic tests on Plasmodium falciparum malaria elimination strategiesHannah C Slater, Amanda Ross, André Lin Ouédraogo, et al.
The Lancet. Global Health|June 2, 2017
Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling studyOliver J Brady, Hannah C Slater, Peter Pemberton-Ross, et al.
The Lancet. Global Health|September 16, 2017
Model citizen - Authors' replyOliver J Brady, Hannah C Slater, Peter Pemberton-Ross, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 22, 2014
Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trialAndré Lin Ouédraogo, Guido J H Bastiaens, Alfred B Tiono, et al.
The Lancet. Infectious Diseases|April 1, 2018
Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trialMenno R Smit, Eric O Ochomo, Ghaith Aljayyoussi, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
The Lancet. Infectious Diseases|January 18, 2020
Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling studyHannah C Slater, Brian D Foy, Kevin Kobylinski, et al.
The Journal of Infectious Diseases|February 9, 2017
Pfhrp2-Deleted Plasmodium falciparum Parasites in the Democratic Republic of the Congo: A National Cross-sectional SurveyJonathan B Parr, Robert Verity, Stephanie M Doctor, et al.
Lancet (London, England)|March 18, 2019
Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trialBrian D Foy, Haoues Alout, Jonathan A Seaman, et al.
Molecular Biology and Evolution|September 8, 2020
Evaluating the Performance of Malaria Genetics for Inferring Changes in Transmission Intensity Using Transmission ModelingOliver J Watson, Lucy C Okell, Joel Hellewell, et al.
JMIR Research Protocols|March 20, 2023
Repeat Ivermectin Mass Drug Administrations for Malaria Control II: Protocol for a Double-blind, Cluster-Randomized, Placebo-Controlled Trial for the Integrated Control of MalariaBrian D Foy, Anthony Some, Tereza Magalhaes, et al.
Nature|December 4, 2015
Assessing the impact of next-generation rapid diagnostic tests on Plasmodium falciparum malaria elimination strategiesHannah C Slater, Amanda Ross, André Lin Ouédraogo, et al.
The Lancet. Global Health|June 2, 2017
Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling studyOliver J Brady, Hannah C Slater, Peter Pemberton-Ross, et al.
The Lancet. Global Health|September 16, 2017
Model citizen - Authors' replyOliver J Brady, Hannah C Slater, Peter Pemberton-Ross, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 22, 2014
Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trialAndré Lin Ouédraogo, Guido J H Bastiaens, Alfred B Tiono, et al.
The Lancet. Infectious Diseases|April 1, 2018
Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trialMenno R Smit, Eric O Ochomo, Ghaith Aljayyoussi, et al.
Pageof 4